Prostate cancer histologic trends in the metropolitan Detroit area, 1982 to 1996

Urology

Volumn 53, Issue 4, 1999, Pages 769-774

  Schwartz, Kendra L ^a,b   Grignon, David J ^a   Sakr, Wael A ^a   Wood Jr , David P ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; INCIDENCE; NEEDLE BIOPSY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MICHIGAN; MIDDLE AGED; PROSTATIC NEOPLASMS; SEER PROGRAM; URBAN POPULATION;

EID: 0033119885     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00575-5     Document Type: Article

References (25)

1. Potosky AL, Miller BA, Albersen PC, et al: The role of increasing detection in the rising incidence of prostate cancer. JAMA 273: 548-552, 1995.
2. Schwartz KL, Severson RK, Gurney JG, et al: Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994. Cancer 15: 1260-1266, 1996.
3. Stephenson RA, Smart CR, Mineau GP, et al: The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induce peak in incidence-data from the Utah cancer registry. Cancer 77: 1342-1348, 1996.
4. Kramer BS, Brown ML, Prorok PC, et al: Prostate cancer screening: what we know and what we need to know. Ann Intern Med 119: 914-923, 1993.
5. Middleton RG: Prostate cancer: are we screening and treating too much? Ann Intern Med 126: 465-467, 1997.
6. Coley CM, Barry MJ, Fleming C, et al: Early detection of prostate cancer. Part II: estimating the risks, benefits, and costs. Ann Intern Med 126: 468-479, 1997.
7. Voss JD: Prostate cancer, screening and prostate-specific antigen: promise or peril? J Gen Intern Med 9: 468-474, 1994.
8. Labrie F, Dupont A, Candas B, et al: Decrease of prostate cancer death by screening: first data from the Quebec prospective and randomized study. Proceedings of the American Society of Clinical Oncology, 1998, Los Angeles, California.
9. Gleason D, and Mellinger G, for the Group at VACUR: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64, 1974.
10. Ohori M, Wheeler TM, Dunn JK, et al: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152: 1714-1720, 1994.
11. Humphrey PA, Keetch DW, Smith DS, et al: Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 155: 816-820, 1996.
12. Demers RY, Swanson GM, Weiss LK, et al: Increasing incidence of cancer of the prostate. The experience of black and white men in the Detroit metropolitan area. Arch Intern Med 154: 1211-1216, 1994.
13. Gilliland FD, Becker TM, Smith A, et al: Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biomarkers Prev 3: 105-111, 1994.
14. McNeal JE, Redwine EA, Freiha ES, et al: Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12: 897-906, 1988.
15. Bostwick DG: Evaluating prostate needle biopsy: therapeutic and prognostic importance. CA Cancer J Clin 47: 297-319, 1997.
16. Bostwick DG: Grading prostate cancer. Am J Clin Pathol 102: S38-S56, 1994.
17. Lee F, Siders DB, Torp-Pedersen ST, et al: Prostate cancer: transrectal ultrasound and pathology comparison. A preliminary study of outer gland (peripheral and central zones) and inner gland (transition zone) cancer. Cancer 67: 1132-1142, 1991.
18. Spires S, Cibull M, Wood DJ, et al: Gleason histologic grading in prostatic carcinoma. Correlation of 18-gauge core biopsy with prostatectomy. Arch Pathol Lab Med 118: 705-708, 1994.
19. Carlson GD, Calvanese CB, Kahane H, et al: Accuracy of biopsy Gleason scores from a large uropathology laboratory: use of a diagnostic protocol to minimize observer variability. Urology 51: 525-529, 1998.
20. Wills ML, Sauvageot J, Partin AW, et al: Ability of sextant biopsies to predict radical prostatectomy stage. Urology 51: 759-764, 1998.
21. Gleason DF: Histologic grading of prostate cancer: a perspective. Hum Pathol 23: 273-279, 1992.
22. Ten Kate FJW, Gallee MPW, Schmitz PIM, et al: Problems in grading prostate carcinoma: interobserver reproducibility of five different grading systems. World J Urol 4: 147-152, 1986.
23. Lessells AM, Burnett RA, Howatson SR, et al: Observer variability in the histopathological reporting of needle biopsy specimens of the prostate. Hum Pathol 28: 646-649, 1997.
24. Scardino P, Weaver R, and Hudson M: Early detection of prostate cancer. Hum Pathol 23: 211-222, 1992.
25. Smith D, and Catalona W: The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 152: 1732-1736, 1994.